Latest Information Update: 09 Dec 2016.
Price : $50 .
At a glance
OriginatorPharmaMar .
- DeveloperFundacion Instituto Valenciano de Oncologia; PharmaMar .
- Class3-ring heterocyclic compounds; Acetates; Alkaloids; Antineoplastics; Dioxolanes; Indoles; Small molecules
- Mechanism of ActionAlkylating agents; Apoptosis stimulants; Cell cycle inhibitors
- Orphan Drug StatusYes - Ovarian cancer
- On Fast trackNo
- New Molecular EntityYes
Highest Development Phases
Phase IIIOvarian cancer; Small cell lung cancer.
- Phase IIBreast cancer; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours.
- Phase ILeukaemia .
Most Recent Events
- 28 Nov 2016Phase-I clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease) in Japan (IV).
- 18 Oct 2016PharmaMar completes enrolment in the Phase-III CORAIL trial for Ovarian Cancer (Second-line therapy or greater) in USA (IV) .
- 10 Oct 2016Efficacy data from a phase II trial in Breast cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016) .
